Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib and Pembrolizumab in Advanced Adrenocortical Carcinoma
NCT06006013Phase 2Recruiting
- Sponsor
- Emory University
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib and pembrolizumab in adrenocortical carcinoma (ACC), sponsored by Emory University. Primary endpoint: Overall Response Rate. Started Jan 2025; status: recruiting.
02
Drugs
cabozantinibpembrolizumab
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT06006013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06006013.